Connect your AI

TG Therapeutics TGTX Gain (loss) on extinguishment of debt

Gain (loss) on extinguishment of debt at other companies

BridgeBio PharmaBBIO

$0+100%

Other financials

Income statement

Revenue$204.9M+69.6%

Gross profit$171.4M+62.8%

Operating income$34.8M+304%

Net income$19.8M+291%

EPS (diluted)$0.12+300%

Balance sheet

Cash & equivalents$442.2M+235%

Total debt$753.6M+197%

Total equity$583.1M+146%

Total assets$1.5B+133%

Cash flow

Operating cash flow-$17.9M+37.7%

CapEx$51.0K+104%

Free cash flow-$17.9M+37.6%

Valuation

Market cap$8.15B-14.3%

Enterprise value$8.46B-11.1%

P/E17.6×-225×

P/S11.6×-13.0×

Profitability

Gross margin83.1%-4.4pp

Operating margin21.3%+5.9pp

Net margin66%+55.8pp

FCF margin-6,328.4%+4,773pp

Returns & leverage

Return on equity112.6%+92.9pp

Debt / equity1.3×+0.2×

Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's gain (loss) on extinguishment of debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is TG Therapeutics's gain (loss) on extinguishment of debt?: TG Therapeutics (TGTX) reported gain (loss) on extinguishment of debt of -$9.15M in Q1 2026.